Pfizer is facing a sharp revenue decline, with Comirnaty vaccine revenue dropping from over $37 billion in 2022 to below $10 billion by 2025. In response to this slump in vaccine sales, Pfizer is pivoting towards oncology acquisitions to offset the decline.
